Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intellia Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intellia Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Intellia Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is NTLA. The reporting company's CIK number is 1652130.
The total value of stock buying since 2005 is $22,999,986.
The total value of stock sales since 2005 is $56,442,930.
The total value of stock option exercises since 2005 is $107,840.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-05-16||Formela Jean Francois (Director)||Sale||6,686||25.04||167,390|
|2018-05-14||Leonard John M. (President and CEO)||Sale||8,400||24.00||201,600|
|2018-03-28||Bell Graeme (EVP, Chief Financial Officer)||Option Ex||8,000||13.48||107,840|
|2018-03-20||Formela Jean Francois (Director)||Sale||39,245||24.42||958,441|
|2018-01-29||Caribou Biosciences, Inc.||Sale||550,645||26.78||14,746,273|
|2017-12-12||Novartis Ag (10% Owner)||Sale||1,523,000||18.30||27,870,900|
|2017-12-08||Bermingham Nessan (President & CEO)||Sale||94,143||20.82||1,960,151|
|2017-12-07||Bermingham Nessan (President & CEO)||Sale||131,140||21.25||2,787,249|
|2017-12-06||Bermingham Nessan (President & CEO)||Sale||111,500||20.56||2,292,328|
|2017-09-13||Caribou Biosciences, Inc.||Sale||1,048,846||.00||0|
|2017-07-11||Atlas Venture Associates Ix, Llc (10% Owner)||Sale||80,000||16.07||1,285,600|
|2017-07-11||Formela Jean Francois (Director)||Sale||80,000||16.07||1,285,600|
|2017-07-10||Atlas Venture Associates Ix, Llc (10% Owner)||Sale||40,000||16.17||646,880|
|2017-07-10||Formela Jean Francois (Director)||Sale||40,000||16.17||646,880|
|2017-07-07||Atlas Venture Associates Ix, Llc (10% Owner)||Sale||30,000||16.77||502,979|
|2017-07-07||Formela Jean Francois (Director)||Sale||30,000||16.77||502,979|
|2017-03-10||Atlas Venture Associates Ix, Llc (10% Owner)||Sale||5,504||14.06||77,408|
|2017-03-10||Formela Jean Francois (Director)||Sale||5,504||14.06||77,408|
|2017-03-09||Atlas Venture Associates Ix, Llc (10% Owner)||Sale||15,628||13.85||216,432|
|2017-03-09||Formela Jean Francois (Director)||Sale||15,628||13.85||216,432|
|2016-05-11||Tls Beta Pte. Ltd. (10% Owner)||Buy||300,000||18.00||5,400,000|
|2016-05-11||Baker Bros. Advisors (gp) Llc (Other)||Buy||200,000||18.00||3,600,000|
|2016-05-11||Gordon Carl L (Director)||Buy||250,000||18.00||4,500,000|
|2016-05-11||Novartis Ag (10% Owner)||Buy||277,777||18.00||4,999,986|
|2016-05-11||Isaly Samuel D (Director)||Buy||250,000||18.00||4,500,000|
Insider trading activities including stock purchases, stock sales, and option exercises of NTLA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intellia Therapeutics, Inc. (symbol NTLA, CIK number 1652130) see the Securities and Exchange Commission (SEC) website.